Alpha-Lipoic Acid: study protocols
11 study groups say how much Alpha-Lipoic Acid participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
3,150 products in our catalogue print how much Alpha-Lipoic Acid a serving holds.
Most common: 25 mg to 50 mg, 22% of 3,150 products.
| Dose per serving | Products |
|---|---|
| 2.5 mg or less | 126 |
| 2.5 mg to 5 mg | 66 |
| 5 mg to 10 mg | 170 |
| 10 mg to 25 mg | 405 |
| 25 mg to 50 mg | 688 |
| 50 mg to 100 mg | 490 |
| 100 mg to 250 mg | 428 |
| 250 mg to 500 mg | 333 |
| 500 mg to 1 g | 369 |
| over 1 g | 75 |
Dose per serving from research
11 study groups in 8 studies say how much Alpha-Lipoic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 55% of 11 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 4 |
| 1 g to 2.5 g | 6 |
Commonly used together
None of these 11 study groups took Alpha-Lipoic Acid with anything else.
11 study groups
| Study | |||
|---|---|---|---|
| Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial 2011 · ALA · Adults aged 18–64 with type 1 or type 2 diabetes and mild-to-moderate diabetic distal symmetric sensorimotor polyneuropathy | 600 mg | 4 years | 230 |
| The beneficial effect of Alpha-lipoic acid supplementation as a potential adjunct treatment in episodic migraines 2022 · ALA group · Women aged 20–50 with episodic migraine without aura and at least two attacks per month | 300 mg | 90 days | 47 |
| Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial 2006 · ALA600 · Adults with diabetes and distal symmetric polyneuropathy; age and sex not specified | 600 mg | 5 weeks | 45 |
| Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial 2016 · α-lipoic acid · Adults with diabetes and mild-to-moderate diabetic polyneuropathy | 600 mg | 4 years | — |
| Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study 2020 · oral ALA · Patients with diabetic peripheral neuropathy; age range and sex not reported | 1.2 g | 26 weeks | 100 |
| Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial 2006 · ALA1200 · Adults with diabetes and distal symmetric polyneuropathy; age and sex not specified | 1.2 g | 5 weeks | 47 |
| Effects of alpha-lipoic Acid on body weight in obese subjects 2011 · alpha-lipoic acid 1200 mg/d · Obese adults with BMI ≥30 kg/m², or BMI 27–30 kg/m² plus hypertension, diabetes mellitus, or hypercholesterolemia | 1.2 g | 20 weeks | — |
| [Efficacy and safety of high-dose α-lipoic acid in the treatment of diabetic polyneuropathy] 2010 · α-lipoic acid · People with diabetes and symptomatic polyneuropathy; age and sex not specified | 1.8 g | 12 weeks | 117 |
| Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial 2006 · ALA1800 · Adults with diabetes and distal symmetric polyneuropathy; age and sex not specified | 1.8 g | 5 weeks | 46 |
| Effects of alpha-lipoic Acid on body weight in obese subjects 2011 · alpha-lipoic acid 1800 mg/d · Obese adults with BMI ≥30 kg/m², or BMI 27–30 kg/m² plus hypertension, diabetes mellitus, or hypercholesterolemia | 1.8 g | 20 weeks | — |